Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18911994 | 0.84 | ADORA2A (0.37) | PDK1PDK2ADORA2AADORA2BDAO | |
| SCHEMBL23520038 | 0.80 | BAZ2B (0.45) | SYKPDK1PDK2ADORA2AADORA2B | |
| SCHEMBL13106283 | 0.73 | ADORA2A (0.64) | ADORA2AADORA2BDAO | |
| SCHEMBL18911885 | 0.72 | MAP2K2 (0.43) | MAPK14DAOGFERGAAALDH1A1 | |
| SCHEMBL21226504 | 0.72 | PDK1 (0.42) | PDK1PDK2ADORA2AADORA2BGAA | |
| SCHEMBL23940247 | 0.71 | KDM4E (0.57) | KCNH2ALDH1A1 | |
| SCHEMBL21936787 | 0.70 | ADORA2A (0.38) | ADORA2AADORA2BDAOALDH1A1 | |
| SCHEMBL22506623 | 0.69 | ELANE (0.41) | PDK1PDK2GAAALDH1A1NPC1 | |
| SCHEMBL30599793 | 0.69 | ELANE (0.41) | PDK1PDK2GAAALDH1A1NPC1 | |
| SCHEMBL13106402 | 0.68 | ADORA2A (0.39) | ADORA2AADORA2BDAOKCNH2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | SYK 3608/4885PDK1 1035/4885PDK2 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.